United States
Ph.D. Scientist and Cross-Functional Leader with a proven track record of translating breakthrough scientific discoveries into operational success across biotechnology startups and major pharmaceutical corporations. Expert at bridging the gap between complex R&D and commercial market readiness, with deep technical expertise spanning gene therapy, molecular immunology, and oncology. Core Expertise & Impact: Gene Therapy & Vector Engineering: Pioneered innovative viral vector designs, including leveraging neurotropic sequences for the transcytosis of therapeutic agents across the blood-brain barrier (BBB). Immunotherapy & Intellectual Property: Co-inventor on foundational patents utilizing chimeric receptors for targeted cytolysis—direct precursors to modern CAR-T cell therapies. Vaccinology & Translational Science: Advanced next-generation vaccine development and elucidated the molecular basis of viral pathogenesis to drive novel therapeutics. Operational Leadership: Seasoned leader of cross-functional teams within both highly regulated biotech environments (such as Applied Immune Sciences and Genelabs) and major pharma ecosystems (including Rhône-Poulenc Rorer/Gencell and Pharmacia & Upjohn). Unique cross-industry experience scaling fast-paced digital platforms, enabling a highly analytical, data-driven approach to scaling laboratory operations and therapeutic pipelines. Act as a critical technical liaison who excels at distilling complex scientific data for Key Opinion Leaders (KOLs) and training commercial teams to maximize market value. Core Competencies: Cross-functional Leadership | Quantitative Analysis | Patent Strategy | Therapeutics Development | Multi-project Management | Technical Communications and Training l Applying big data to molecular approaches and strategies
Senior Research Investigator - Molecular Immunologist, Vaccine Design, Viral Pathogenesis Synthetic Epitope Vaccine Design: Conceived and evaluated novel vaccine strategies against high-risk Human Papillomaviruses (HPV) utilizing synthetic, hypervariable epitope constructs (HECs) engineered to overcome viral antigenic drift and strain diversity. Broad-Spectrum Immunogenicity: Demonstrated that multiplexed hypervariable peptide constructs could successfully prime the immune system to recognize conserved structural and regulatory motifs, inducing high-titer, cross-reactive antibody and T-cell responses against multiple oncogenic HPV genotypes. Assay Development & Characterization: Developed and executed rigorous immunological assays (including ELISAs, lymphocyte proliferation assays, and neutralization assays) to map epitope dominance, evaluate serum cross-reactivity, and quantify cellular immune responses in vivo. Preclinical Platform Validation: Co-led the translational pipeline from computational epitope selection and synthetic peptide fabrication to preclinical evaluation, proving the viability of HEC platforms for complex, multi-strain viral targets. Core Publication Representing this Tenure: Reddy, K. J., Banapour, B., Anderson, D. E., Lee, S. H., Marquez, J. P., Carlos, M. P., Torres, J. V. Induction of immune responses against human papillomaviruses by hypervariable epitope constructs. Immunology, 112(2): 321–327.
Infectious Disease Specialist; Pharmacia & Upjohn [company was later acquired by Pfizer] Led critical scientific and operational activities contributing to the successful market launch of Rescriptor (Delavirdine), a non-nucleotide reverse transcriptase inhibitor. Led critical scientific and operational initiatives contributing to the successful market launch of [Drug Name/Therapeutic Class]. Cross-Functional Collaboration: Served as the central scientific liaison, partnering directly with Product Managers, Marketing, and Medical Science Liaisons (MSLs) to align complex clinical data with commercial go-to-market strategies. Launch Readiness & Strategy: Completed intensive clinical training on drug "Features, Advantages, and Benefits" (FABs), ensuring total technical accuracy and regulatory compliance in promotional and educational messaging. Strategic Commercial Support: Translated high-level clinical trial findings into actionable insights for the commercial team, facilitating influential presentations to key opinion leaders (KOLs) and external stakeholders. Operational Integration: Bridged the gap between R&D and commercial operations by developing unified communication frameworks that ensured consistent scientific messaging across all departments.
Applied Immune Sciences / Rhône-Poulenc Rorer (Gencell) Senior Scientist | Cell Processing & Chimeric Receptor Engineering Pioneering CAR-T Engineering: Conceived and executed early-stage gene therapy initiatives that formed the early scientific framework of Chimeric Antigen Receptor (CAR-T) development, further demonstrating that engineered T-cells can bypass traditional major histocompatibility complex (MHC) restriction to eliminate solid tumors. Seminal Construct Design & Lysis Validation: Designed, cloned, and functionally validated novel heregulin-zeta chimeras, combining natural ligands with the CD3-$\zeta$ signaling chain to successfully redirect primary human CD8+ cytotoxic T-lymphocytes (CTLs) to target and lyse HER3/HER4-overexpressing malignancies. Ex Vivo Bioprocess Scale-Up: Partnered with cellular immunology pioneers, including Dr. Dewey Moody, to advance clinical-scale, closed-system T-cell isolation, purification, and ex vivo culture methodologies; optimized robust expansion protocols for therapeutic CD4+ and CD8+ subsets using antibody-coated solid-phase selection platforms (AIS Cellector). Vector Integration & Transduction: Streamlined high-efficiency viral and non-viral gene transfer protocols to stably express chimeric transcripts in primary human effector cells, establishing crucial benchmarks for modern autologous cell therapy manufacturing. Core Publication Representing this Tenure: Muniappan, A., Banapour, B., Lebkowski, J., Talib, S. Ligand-mediated cytolysis of tumor cells: use of heregulin-zeta chimeras to redirect cytotoxic T-lymphocytes. Cancer Gene Therapy, 7(1): 128-134.
• U.S. Patent No. 5,851,828 – Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells • U.S. Patent No. 6,284,240 – Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells • U.S. Patent No. 6,753,162 – Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells • U.S. Patent No. 7,094,599 – Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells • U.S. Patent Application No. 20030138410 – Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells. B. Seed, B. Banapour, W. Kolanus, C. Romeo. This family of patents was licensed to Hoechst Ag Inventors: Brian Seed, Babak Banapour, Charles Romeo, Waldemar Kolanus Assignee: General Hospital Corporation (Massachusetts General Hospital) Description: This pioneering invention details chimeric CD4 receptors designed to direct cytotoxic T lymphocytes (T-cells) to target and destroy HIV-infected cells. This framework laid foundational groundwork for modern redirected T-cell and CAR-T therapies. The global footprint of these inventions and their subsequent impact on advanced biotechnology reveals extensive international reach and a foundational role in the evolution of CAR-T therapy.